Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Efforts to prevent infections and keep vulnerable people out of hospital are beginning to pay off, but deploying these strategies presents new challenges.
The consequences of respiratory syncytial virus infection sometimes linger for years — and scientists are trying to work out whether there’s a causal link.
Respiratory syncytial virus is usually associated with babies, but the virus can also cause serious disease in older adults and people with chronic medical conditions.
If deployed effectively and equitably, this latest generation of vaccines could help to prevent countless deaths and hospitalizations among the young and old.
Scientists are racing to control malaria in northern Brazil where the disease is playing a major part in the current health emergency threatening the region’s Indigenous people.
Concerns that artemisinin combination treatments are losing their effectiveness against Plasmodium parasites have set scientists looking for alternatives.
Hot on the heels of the first approved vaccine for malaria, researchers are racing to develop even better shots that tackle the parasite at every stage of its life cycle.